Nuvectis Pharma, Inc. (NVCT)
23.04
+0.31
(+1.36%)
USD |
NASDAQ |
Sep 01, 16:00
23.52
+0.48
(+2.08%)
After-Hours: 19:29
Nuvectis Pharma Cash from Operations (TTM) : -19.51M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -19.51M |
| March 31, 2026 | -18.35M |
| December 31, 2025 | -16.01M |
| September 30, 2025 | -14.50M |
| June 30, 2025 | -12.41M |
| March 31, 2025 | -12.06M |
| December 31, 2024 | -12.25M |
| September 30, 2024 | -13.63M |
| June 30, 2024 | -14.47M |
| March 31, 2024 | -15.54M |
| Date | Value |
|---|---|
| December 31, 2023 | -15.95M |
| September 30, 2023 | -15.62M |
| June 30, 2023 | -16.80M |
| March 31, 2023 | -15.26M |
| December 31, 2022 | -13.56M |
| September 30, 2022 | -11.11M |
| June 30, 2022 | -11.11M |
| March 31, 2022 | -12.58M |
| December 31, 2021 | -9.504M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Decoy Therapeutics, Inc. | -8.324M |
| Unicycive Therapeutics, Inc. | -27.84M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Anika Therapeutics, Inc. | 5.977M |